BioSpace News Archive

The Alpha-1 Foundation announces the appointment of Andrew A. Wilson, MD as its new Scientific Director.

The global histology and cytology market size is expected to be worth around US$ 47.7billion by 2030, according to a new report by Vision Research Reports.

Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX) today announced the pricing of a public offering of an aggregate of 1,042,787 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-3 warrants to purchase up to 1,042,787 shares of common stock and Series A-4 warrants to purchase 1,042,787 shares of common stock, at a combined public offering price of $4.795 per share (or pre-funded warrant) and accompanying warrants.

Cure, a healthcare innovation campus in New York City, announced today that it will host an in-person and virtual fireside chat featuring Pulitzer Prize-winner and New York Times bestselling author, Siddhartha Mukherjee, as he kicks off the launch of his newest book release, The Song of the Cell: An Exploration of Medicine and the New Human.

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that the Company granted stock options to three non-executive employees to purchase an aggregate of 84,000 shares of common stock.

Aeglea BioTherapeutics, Inc. announced that the compensation committee of its board of directors has granted non-qualified stock options to purchase an aggregate of 1,884,838 shares of Aeglea’s common stock to Jeffrey M. Goldberg as a material inducement to his appointment as the chief executive officer of Aeglea in accordance with Rule 5635 of the Nasdaq Listing Rules.

Anavex Life Sciences Corp. announced that management will host a conference call on Monday December 5, 2022, at 8:30 am ET to review ANAVEX®2-73-AD-004 Alzheimer’s disease Phase 2b/3 study results.

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, announced that the Company granted stock options to two new employees to purchase an aggregate of 62,800 shares of the Company’s common stock, effective as of December 1, 2022.

RedHill Biopharma Ltd. today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $8.0 million.

EIP Pharma Inc. today announced that a presentation at the 15th Annual Clinical Trials in Alzheimer’s disease (CTAD) meeting in San Francisco demonstrates that neflamapimod may reverse pathologic disease progression in the basal forebrain cholinergic system in the early stages of Alzheimer’s disease.